PBAC's latest decision on Insulin detemir: Recommended with restriction (2007). Considered for people with type 2 diabetes who are not responsive to oral hypoglycaemic drugs.
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2005
Submissions
3
2005 → 2007
Eligible population
people with type 2 diabetes who are not responsive to oral hypoglycaemic drugs
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Other
Key trials
Study 1373, Study 1431, Study 2175
Comparator
insulin glargine
Economic model
Cost-minimisation
Budget impact
$10M
Eligible patients/year
10,000
ICER note
Cost-minimisation analysis presented; no ICER calculated
Submission history
Jul 2005: Deferred · Authority Required
Mar 2006: Recommended with restriction
Nov 2007: Recommended with restriction · Unrestricted